What is One Drop?
Founded in 2015 and headquartered in New York City, One Drop is a sophisticated diabetes management platform that integrates mobile computing with advanced data science. The company empowers users to track daily activities, including nutrition, insulin administration, and physical exercise, to visualize the complex correlations between these variables and glucose levels. By transforming raw health data into actionable insights, One Drop addresses the critical need for proactive, patient-centric chronic disease management. Its market position is defined by a commitment to evidence-based digital health solutions that bridge the gap between clinical care and daily lifestyle management.
How much funding has One Drop raised?
One Drop has raised a total of $154.4M across 6 funding rounds:
Angel/Seed
$1M
Series A
$8.6M
Private Equity
$6.1M
Series B
$40M
Corporate Investment
$64M
Series C
$34.7M
Angel/Seed (2015): $1M, investors not publicly disclosed
Series A (2015): $8.6M led by RRE Ventures LLC., Launch, Neulogy Ventures, Capital Factory companies, and Box Group
Private Equity (2017): $6.1M, investors not publicly disclosed
Series B (2019): $40M featuring Bayer
Corporate Investment (2020): $64M backed by Bayer
Series C (2020): $34.7M with participation from Bayer
Key Investors in One Drop
Bayer
A global enterprise with core competencies in life sciences, focusing on pharmaceuticals, consumer health, and crop science to improve human health and sustainable food security.
RRE Ventures LLC.
A venture capital firm dedicated to supporting founders at critical stages of their business journey through long-term partnerships and strategic investment.
Box Group
An early-stage investment fund that focuses on technology companies across various sectors, including fintech and software, by backing visionary founders at the earliest stages.
What's next for One Drop?
With the infusion of capital from its latest funding rounds, One Drop is well-positioned to accelerate its product development roadmap and deepen its integration with global healthcare ecosystems. The strategic alignment with major life science partners suggests a focus on scaling its digital therapeutics platform to address a broader spectrum of chronic conditions beyond diabetes. Future growth will likely center on enhancing predictive analytics capabilities and expanding its footprint in international markets, where the demand for remote patient monitoring and data-driven health management continues to rise. The company remains a key entity to watch as it transitions toward broader enterprise-level adoption and long-term clinical impact.
See full One Drop company page
